Conditions: Lymphoma, B-Cell
Keywords: B-Cell Non-Hodgkin's Lymphoma
Allocation: NON_RANDOMIZED | Intervention model: 
Enrollment: 79
Healthy volunteers: no

Brief summary:
To determine the Maximum Tolerated Dose (MTD), the tolerability, and the initial safety profile of CMC-544 in subjects with B-cell Non-Hodgkin's Lymphoma (NHL).

Detailed description:

Arms:
arm 1: Inotuzumab ozogamicin, iv, dose escalation and expanded cohort at 1.8mg/m2

Interventions: intervention 1: Inotuzumab ozogamicin [CMC-544]
Intervention descriptions: intervention 1: CMC-544, IV, dose escalation trial

Protocol document: